Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine as Add-on for Acutely Suicidal Depressed Inpatients
NCT00863291Phase 3Unknown
- Sponsor
- Abarbanel Mental Health Center
- Start
- Nov 2007
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of buprenorphine in suicidal ideation, major depressive disorder (MDD), sponsored by Abarbanel Mental Health Center. Status: unknown.
02
Drugs
buprenorphine
03
Conditions
suicidal ideationmajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00863291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00863291.